Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Retronasal olfactory recovery during biologic therapy for chronic rhinosinusitis with nasal polyps: a prospective longitudinal study with parallel orthonasal assessment.

Created on 30 Oct 2026

Authors

P Boscolo-Rizzo, L Raimondo, G Spinato, A Tracanelli, E Provenzano, M Tattoni, G Giunta, E Biancoli, F Copersito, A Maniaci, L A Vaira, G Tirelli, G Ottaviano

Published in

Rhinology. Oct 30, 2026. Epub Oct 30, 2026.

Abstract

Olfactory dysfunction is a key feature of chronic rhinosinusitis with nasal polyps (CRSwNP). While biologics improve orthonasal olfaction, longitudinal data on retronasal function and differences between inflammatory targets remain limited. This study evaluated retronasal olfactory recovery over time during biologic therapy and compared IL-4/IL-13 versus IL-5 pathway blockade.
In this prospective longitudinal study, adults with severe CRSwNP starting biologics were assessed at baseline and after 4, 12, and 24 weeks. Orthonasal olfaction was measured using Sniffin' Sticks (TDI), and retronasal function with a validated 20-item identification test. Clinical outcomes included nasal polyp score (NPS), peak nasal inspiratory flow, and SNOT-22. Repeated-measures ANOVA was used to evaluate longitudinal changes and time-by-treatment interactions.
Sixty-nine patients were included (44 dupilumab, 25 mepolizumab). At baseline, mean TDI was 15.0 and retronasal score 7.2, indicating severe impairment. All outcomes improved significantly over time. Retronasal function improved rapidly within 4 weeks (7.2 to 10.4). TDI increased progressively (15.0 to 26.0 at 24 weeks). Significant time-by-treatment interactions were observed for retronasal identification, TDI, SNOT-22, and NPS, indicating non-parallel recovery patterns with dupilumab being associated with greater improvements in retronasal function and symptoms compared with mepolizumab.
Biologic therapy leads to substantial recovery of both retronasal and orthonasal olfaction in CRSwNP, with distinct considetemporal dynamics. Retronasal function shows rapid improvement and may be particularly sensitive to IL-4/IL-13 blockade, supporting its potential role as an early functional marker of response to biologic therapy.

PMID:
42958882
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 61
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement